Guardant Health Inc. (GH) Reports Q3 Loss of $1.94, Revenues Beat; Offers FY18 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guardant Health Reports Third Quarter 2018 Financial Results
November 19, 2018 4:05 PM ESTRevenue growth of 95% over prior year period
REDWOOD CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the third quarter ended September 30, 2018.
Recent Highlights
Revenues of $21.7 million for the third quarter of 2018, representing a 95% increase over the third quarter of 2017Reported 7,027 tests to clinical customers and 2,505 tests to biopharmaceutical customers in... More